All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
On September 4, 2020, the U.S. Food and Drug Administration (FDA) accepted a supplemental biologics license application (sBLA) for axicabtagene ciloleucel (axi-cel) for the treatment of patients with relapsed or refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL) after two or more prior lines of systemic therapy.1
Axi-cel, an anti-CD19 autologous chimeric antigen receptor (CAR) T-cell product, is already approved for the treatment of adult patients with R/R large B-cell lymphoma (LBCL) after ≥ 2 lines of systemic therapy, and previously the FDA granted breakthrough therapy designation to axi-cel for R/R FL or MZL. In case of approval, axi-cel would be the first commercial CAR T-cell therapy approved for R/R FL or MZL.
The sBLA submission was based on data from the ongoing single-arm, multicenter, open-label, phase II ZUMA-5 trial (NCT03105336). Interim results of this study were reported at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. Axi-cel showed high rates of durable responses and a manageable safety profile (read the full article on the ZUMA-5 study, here).
Axi-cel could represent a valid treatment option for patients with late line R/R FL and MZL who have exhausted other approved treatment options.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?